TPTX

Turning Point Therapeutics is a biopharmaceutical firm specializing in precision oncology, currently in the clinical development stage. The company is dedicated to discovering and advancing targeted therapies that address the underlying genetic causes of cancer. They have developed a portfolio of innovative tyrosine kinase inhibitors (TKIs) designed to treat cancer patients, including those who have not yet received TKI treatment and those who have previously been treated with TKIs. Their flagship experimental compound, repotrectinib, is currently undergoing evaluation in the Phase 1/2 TRIDENT-1 clinical study. This trial is aimed at individuals with advanced non-small-cell lung cancer (NSCLC) characterized by ROS1 positivity, as well as those with advanced solid tumors exhibiting ROS1 and NTRK mutations. The company's developmental pipeline further includes TPX-0022, a MET/SRC/CSF1R inhibitor, which is in a Phase 1 SHIELD-1 trial for advanced solid tumors carrying MET genetic abnormalities. Additionally, TPX-0046, a RET inhibitor, is progressing through its Phase 1/2 SWORD-1 clinical trial for advanced solid tumors with RET genetic variations. Finally, TPX-0131, an ALK inhibitor, is being investigated in the Phase 1/2 FORGE-1 study for patients with advanced or metastatic ALK-positive NSCLC who have previously undergone TKI therapy. Established in San Diego, California, in 2013, Turning Point Therapeutics became a subsidiary of Bristol-Myers Squibb Company on August 15, 2022.